Doliver Advisors LP Purchases New Holdings in Novo Nordisk A/S (NYSE:NVO)

Doliver Advisors LP acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,773 shares of the company’s stock, valued at approximately $1,383,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Morgan Stanley grew its holdings in shares of Novo Nordisk A/S by 96.5% in the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after acquiring an additional 4,526,199 shares in the last quarter. Folketrygdfondet boosted its position in shares of Novo Nordisk A/S by 2.7% in the 4th quarter. Folketrygdfondet now owns 8,631,264 shares of the company’s stock worth $892,904,000 after purchasing an additional 225,822 shares in the last quarter. Capital International Investors lifted its position in Novo Nordisk A/S by 22.3% in the 4th quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock valued at $736,121,000 after acquiring an additional 1,297,536 shares in the last quarter. Royal Bank of Canada raised its stake in Novo Nordisk A/S by 109.2% during the 3rd quarter. Royal Bank of Canada now owns 3,643,061 shares of the company’s stock valued at $331,300,000 after buying an additional 1,901,429 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Novo Nordisk A/S by 110.4% during the 3rd quarter. Northern Trust Corp now owns 3,585,407 shares of the company’s stock valued at $326,057,000 after buying an additional 1,881,264 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded up $0.29 during midday trading on Monday, hitting $142.25. The company had a trading volume of 2,988,899 shares, compared to its average volume of 4,459,286. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $144.50. The business has a 50-day simple moving average of $133.31 and a two-hundred day simple moving average of $122.37. The firm has a market capitalization of $638.35 billion, a price-to-earnings ratio of 49.05, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. The company had revenue of $9.52 billion during the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on NVO. The Goldman Sachs Group assumed coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target for the company. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price for the company. Argus lifted their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, June 17th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $145.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.